|
Forecast
Period
|
2026-2030
|
|
Market
Size (2024)
|
USD
5.86 Billion
|
|
CAGR
(2025-2030)
|
6.38%
|
|
Fastest
Growing Segment
|
Immunoassay
|
|
Largest
Market
|
Germany
|
|
Market
Size (2030)
|
USD 8.40 Billion
|
Market Overview
Europe
Biomarker Technologies Market was valued at USD 5.86 Billion in 2024 and is
expected to reach USD 8.40 Billion by 2030 with a CAGR of 6.38%. As chronic
diseases such as cancer, cardiovascular disorders, and autoimmune conditions
become more prevalent, the need for early detection and targeted treatment has
intensified. Biomarkers, which serve as measurable indicators of biological
processes or responses, are becoming essential tools for diagnostics,
therapeutic monitoring, and drug development, particularly in the context of
personalized healthcare. One of the key factors propelling the market is the
widespread adoption of non-invasive testing methods, including liquid biopsies.
These
technologies enable the detection of disease-specific biomarkers in body fluids
such as blood or urine, offering a convenient and less intrusive alternative to
traditional tissue biopsies. Their utility in oncology is particularly
significant, as they allow for real-time tracking of tumor dynamics and
treatment response. This trend aligns with Europe’s growing emphasis on
personalized medicine, where biomarker-guided therapies are increasingly being
used to tailor treatment strategies to individual patient profiles. Despite the promising outlook, the
market does face certain challenges. High development costs, stringent
regulatory frameworks, and the need for standardization across testing
methodologies can pose barriers to widespread adoption.
Key Market Drivers
Growth in Healthcare Industry
The
continued expansion of the healthcare industry across Europe is a significant
driver of the biomarker technologies market. Per capita healthcare
expenditures are projected to rise substantially, particularly across Europe.
Spending is anticipated to accelerate in the coming years, with European
nations expected to increase their healthcare budgets by an average of 6.5%
annually through 2030. Artificial intelligence is poised to play a critical
role in helping mitigate the pace of this cost escalation. Increasing
healthcare expenditure, an aging population, and a growing prevalence of
chronic and lifestyle-related diseases are creating a favorable environment for
the adoption of advanced diagnostic and therapeutic technologies, including
biomarkers.
Biomarker
technologies are gaining prominence as healthcare systems across Europe shift
toward precision and personalized medicine. The quality of biomarker testing
is particularly advanced in Western and Northern Europe, where more than 90% of
laboratories actively participate in established quality assurance schemes,
ensuring high standards of accuracy, reliability, and consistency in diagnostic
practices. Governments and private healthcare institutions are investing
heavily in research and development to improve early disease detection, patient
stratification, and targeted therapies. These investments are accelerating the
integration of biomarker-based diagnostics into clinical workflows,
particularly in areas such as oncology, neurology, and cardiovascular care.
Surge in Technological
Advancements
The
Europe biomarker technologies market is experiencing robust growth, largely
driven by rapid advancements in technology that are reshaping the landscape of
clinical diagnostics, drug development, and personalized medicine. Genomics,
which involves the identification and characterization of genes and their
unique functions, has recently emerged as a powerful tool in the drug discovery
process. The integration of genomics into drug development across Europe has
consequently paved the way for the creation of more effective and safer
pharmaceutical therapies. These innovations are enabling faster, more
accurate, and cost-effective identification and analysis of biomarkers,
positioning Europe at the forefront of biomedical research and healthcare
transformation.
One
of the primary contributors to this growth is the evolution of high-throughput
platforms such as next-generation sequencing (NGS), mass spectrometry, and
multi-omics technologies. These tools have significantly improved the
sensitivity and specificity of biomarker detection, enabling the simultaneous
analysis of large volumes of genomic, proteomic, and metabolomic data. This
capability is particularly crucial in the fields of oncology, neurology, and
rare disease diagnostics, where early and precise biomarker identification is
essential for timely intervention and targeted treatment strategies.
Download Free Sample Report
Key Market Challenges
High Cost of Development
The
high cost of development represents a significant challenge within the Europe
biomarker technologies market. Despite growing interest in biomarker-driven
diagnostics and personalized medicine, the path from discovery to clinical
application remains financially demanding and resource-intensive. The
development of biomarker technologies involves extensive research, complex
validation processes, and rigorous clinical trials, all of which require
substantial investment over long timeframes.
A
major portion of the costs arises during the early stages of biomarker
discovery, where advanced platforms such as genomics, proteomics, and
metabolomics are used to identify potential candidates. These processes often
involve high-throughput screening, sophisticated instrumentation, and
specialized expertise, driving up research expenditures. Furthermore, the
transition from discovery to clinical use requires comprehensive validation
across diverse patient populations to ensure safety, specificity, and
reproducibility. These requirements extend development timelines and escalate
operational costs.
Key Market Trends
Rise of Liquid Biopsies &
Non‑Invasive
Testing
The
growing adoption of liquid biopsies and non-invasive testing represents a
transformative trend in the Europe biomarker technologies market. As healthcare
systems increasingly prioritize early detection, patient comfort, and real-time
disease monitoring, these minimally invasive diagnostic approaches are gaining
widespread traction across the region. In 2022, the Swiss biotechnology firm
introduced a blood-based solution that significantly simplifies the
identification of regulatory-approved therapies for individual cancer patients,
empowering hospital laboratories to perform clinically actionable liquid
biopsies on-site.
Liquid
biopsies, which involve the analysis of biomarkers such as circulating tumor
DNA (ctDNA), exosomes, and circulating tumor cells (CTCs) from blood or other
bodily fluids, are emerging as a valuable alternative to traditional tissue
biopsies. Their non-invasive nature reduces the risks associated with
conventional procedures, enables repeated sampling, and facilitates the
detection of disease progression or recurrence with greater ease. This is
particularly significant in oncology, where early identification of genetic
mutations and resistance markers can greatly enhance treatment precision.
Segmental Insights
Technology Insights
Based
on Technology, Immunoassay have emerged as the fastest growing segment in the Europe
Biomarker Technologies Market in 2024. One of the key factors behind this
growth is the widespread application of immunoassays in the detection of cancer
biomarkers, infectious diseases, cardiovascular conditions, and autoimmune
disorders. Their high sensitivity and specificity make them particularly
effective for screening large patient populations, monitoring disease
progression, and evaluating therapeutic efficacy. As healthcare providers in
Europe increasingly focus on preventive care and precision medicine,
immunoassays are being integrated into routine diagnostic workflows, thereby
expanding their market presence.
Indication Insights
Based
on Indication, Oncology have emerged as the fastest growing segment in the Europe
Biomarker Technologies Market during the forecast period. Cancer remains one of
the leading causes of mortality across Europe, prompting healthcare systems to
prioritize improved diagnostic tools and personalized treatment strategies.
Biomarkers play a pivotal role in enabling early detection, monitoring disease
progression, predicting therapeutic response, and identifying specific genetic
mutations that guide targeted therapies. This shift from a one-size-fits-all
approach to personalized oncology care has significantly elevated the demand
for biomarker-based technologies.
Download Free Sample Report
Country Insights
Based
on Country, Germany have emerged as the dominating country in the Europe
Biomarker Technologies Market in 2024. This is due to its robust healthcare
infrastructure, strong research ecosystem, and substantial public and private
sector investment in precision medicine. The country is home to a dense network
of leading academic institutions, biotechnology companies, and clinical
research organizations that actively contribute to biomarker discovery,
validation, and commercialization. This advanced research landscape enables
Germany to remain at the forefront of innovation, particularly in genomics,
proteomics, and digital diagnostics.
Recent Development
- In
April 2025, the Viromarkers project was officially launched in Rome, Italy,
with backing from the Innovative Health Initiative Joint Undertaking (IHI JU)
and its member organizations. This collaborative effort unites researchers from
public institutions, representatives from Europe’s life sciences industry, and
patient associations from across the continent. The project aims to identify
and validate novel biomarkers that could transform clinical care for patients
affected by HIV, Hepatitis D (HDV), and Cytomegalovirus (CMV). Its objectives
include improving the monitoring of treatment responses, refining therapeutic
approaches, and advancing the understanding of disease progression in
immunosuppressed individuals.
- In
May 2025, AMRA Medical announced the much-anticipated launch of its
next-generation AMRA BCP Scan service powered by the AMRA Profiler in both its
home market of Sweden and in Germany, marking the introduction of the device
across EU markets. The AMRA BCP Scan service offers clinicians advanced fat
distribution measurements, including liver fat, alongside muscle composition
biomarkers to deliver a comprehensive body composition profile (BCP) that
supports the evaluation of individual health risks. Deployed directly at the
clinic, the service enables fast, precise, and standardized body composition
assessments, delivering highly accurate, patient-specific insights.
- In
September 2024, Takara Bio Europe, a wholly owned subsidiary of Takara Bio
Inc., unveiled the Shasta Single-Cell System during the 2024 Human Cell Atlas
General Meeting. This advanced, high-throughput next-generation sequencing
(NGS) platform is designed to accelerate biomarker discovery in oncology
research. By integrating robust, validated chemistries with intuitive
bioinformatics tools, the system enables researchers to extract significantly
more genomic and transcriptomic data from a larger pool of cells than was
previously achievable while simultaneously streamlining workflows to reduce
both time and operational costs.
- In
May 2024, Seer, Inc., a prominent life sciences company advancing a transformative
platform in proteomics, announced the opening of the Seer Technology Access
Center (STAC) in Bonn, Germany. This new facility aims to support the European
biopharma and life sciences sectors by offering specialized service programs
and access to advanced mass spectrometry technologies, enabling more
comprehensive and unbiased proteomic research. The establishment of STAC in
Europe addresses a critical gap for researchers seeking to conduct in-depth
proteomic studies to accelerate biomarker discovery and drug development.
Key Market Players
- F.
Hoffmann-La Roche AG
- Merck
KGAA
- Beckman
Coulter, Inc.
- Qiagen
N.V.
- Biomérieux
SA
- Bio-Rad
Laboratories N.V.
- Siemens
AG
- Abbott
Molecular Inc.
- Danaher
Corporation
- Epigenomics
AG
|
By
Technology
|
By
Indication
|
By
Country
|
- Immunoassay
- DDPCR
- Next
Generation Sequencing (NGS)
- Mass
Spectrometry
- DHPLC
- Others
|
- Oncology
- Infectious Diseases
- Autoimmune Disorders
- Cardiovascular Disorders
- Others
|
- Germany
- Italy
- United
Kingdom
- France
- Spain
- Rest
of Europe
|
Report Scope
In this report, the Europe Biomarker Technologies
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Europe Biomarker Technologies Market, By Technology:
o Immunoassay
o DDPCR
o Next Generation Sequencing (NGS)
o Mass Spectrometry
o DHPLC
o Others
- Europe Biomarker Technologies Market, By Indication:
o Oncology
o Infectious Diseases
o Autoimmune Disorders
o Cardiovascular Disorders
o Others
- Europe Biomarker Technologies Market, By Country:
o Germany
o Italy
o United Kingdom
o France
o Spain
o Rest of Europe
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Europe
Biomarker Technologies Market.
Available Customizations:
Europe Biomarker Technologies Market report with
the given market data, Tech Sci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Europe Biomarker
Technologies Market is an upcoming report to be released soon. If you wish an
early delivery of this report or want to confirm the date of release, please
contact us at [email protected]